← Back to Home

Restoring Insulation to Damaged Nerve Fibers: Small Molecule CN045 Promotes Remyelination in Mouse Brains

CN045 can promote the maturation of human and mouse oligodendrocyte progenitor cells and increase remyelination in white and gray matter in a demyelinated mouse model; however, its metabolism is too rapid and its target remains unclear, leaving it some distance from human trials.

By SURL BioNews

Most existing drugs for multiple sclerosis focus on suppressing immune attacks but struggle to repair axons that have already lost their protective myelin. A study has now identified CN045 from 20,000 small molecules selected for their tendency to enter the central nervous system. It not only induced myelin-producing cells to mature in culture but also promoted the formation of new myelin in damaged regions of mouse brains, adding an early candidate scaffold to a therapeutic strategy aimed at “repair” rather than merely “damage control.”

Myelin acts like an insulating layer around nerve fibers and is produced by oligodendrocytes. After multiple sclerosis causes repeated myelin damage, both neural signal transmission and axonal survival are affected. Although the adult brain retains oligodendrocyte progenitor cells (OPCs), which can migrate to lesions and differentiate into mature, myelin-producing cells, this repair capacity often fails as the disease progresses.

The research team conducted a phenotypic screen using mouse OPCs, initially identifying 390 hits from 20,000 compounds before narrowing them to 18 molecules with half-maximal effective concentrations below 200 nanomolar. CN045 had a half-maximal effective concentration of approximately 40 nanomolar; in mouse cell experiments, its differentiation-promoting effect exceeded that of the commonly used positive control triiodothyronine T3. The cells not only expressed myelin proteins such as PLP and MBP but also formed longer myelin-like sheaths along nanofibers that mimic nerve axons.

The results in human cells provided an additional layer of support. Researchers used three cortical tissue samples obtained during surgery for refractory epilepsy and isolated OPCs from them. After 14 days of CN045 treatment, both the proportion of mature cells and the myelin-like sheathing on nanofibers were greater than with the solvent control. However, the samples came from only three donors with widely differing ages. This experiment demonstrates that human cells can respond, but it is not sufficient to infer efficacy in patients’ brains.

For the animal experiments, researchers first used cuprizone and rapamycin to induce chronic demyelination in mice, followed by daily intraperitoneal injections of CN045 for six weeks. Compared with the vehicle control, treated mice showed more remyelination in the corpus callosum, hippocampus, and cerebral cortex, encompassing both white and gray matter; each group included 10 to 12 mice. However, the paper also described the increase as statistically significant but still limited in magnitude. Moreover, this toxin-induced model does not reproduce the immune attacks central to multiple sclerosis, nor did the study demonstrate accompanying improvements in neurological function or behavior.

CN045 had already been reported in a 2023 conference abstract to promote the maturation of mouse and human OPCs, with transcriptomic analysis indicating that cholesterol synthesis pathways might be involved. This full study provides further details on the screening process, the sheathing capacity of human cells, and evidence of remyelination in the brain, but the actual molecular target remains undetermined. A more immediate development obstacle is its in vivo half-life of only approximately 2.7 hours, while risks involving hepatocyte clearance, cytochrome P450, and potential hERG inhibition still need to be ruled out. The research team has tested multiple structural analogs, indicating that the chemical scaffold still has room for modification. Until safety, exposure, and functional efficacy are more firmly validated, CN045 should be regarded as a lead compound rather than a multiple sclerosis therapy ready to enter clinical development.

References

  1. npj Drug Discovery
  2. ECTRIMS 2023